Compare NFG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | KRYS |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | NFG | KRYS |
|---|---|---|
| Price | $82.47 | $215.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $91.20 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 597.8K | 325.5K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 576.19 | 275.72 |
| EPS | 5.68 | ★ 6.66 |
| Revenue | ★ $2,277,541,000.00 | $373,164,000.00 |
| Revenue This Year | $21.84 | $34.33 |
| Revenue Next Year | $13.95 | $48.04 |
| P/E Ratio | ★ $14.52 | $32.72 |
| Revenue Growth | 17.11 | ★ 54.51 |
| 52 Week Low | $59.01 | $122.80 |
| 52 Week High | $94.13 | $221.84 |
| Indicator | NFG | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 67.03 |
| Support Level | $79.12 | $213.24 |
| Resistance Level | $81.94 | $221.84 |
| Average True Range (ATR) | 1.39 | 6.76 |
| MACD | 0.52 | 0.37 |
| Stochastic Oscillator | 94.50 | 70.51 |
National Fuel Gas Co is a diversified energy company engaged in the production, gathering, transportation, distribution, and marketing of natural gas. The operating segments of the company are the Exploration and Production segment, the Pipeline and Storage segment, the Gathering segment, and the Utility segment. The company generates a majority of its revenue from the Exploration and Production segment which is engaged in the exploration for, and the development and production of, natural gas in the Appalachian region of the United States. Geographically, the company operates in the United States.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.